User:Thelansis/sandbox

Nonalcoholic Fatty Liver Disease & NASH
Definition & Facts

Nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver. Nonalcoholic steatohepatitis (NASH) is a type of NAFLD. If you have NASH, you have inflammation and liver cell damage, along with fat in your liver.

Symptoms & Causes

Usually, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) cause few or no symptoms. Certain health conditions—including obesity, metabolic syndrome, and type 2 diabetes—make you more likely to develop NAFLD and NASH.

Diagnosis

Doctors use your medical history, a physical exam, and tests to diagnose nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Tests may include blood tests, imaging tests, and sometimes liver biopsy.

Treatment

Doctors recommend weight loss to treat nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Weight loss can reduce fat in the liver, inflammation, and fibrosis. No medicines have been approved to treat NAFLD and NASH.

Management

General measures for all patients — The following measures apply to all patients with NAFLD:


 * Refrain from alcohol- Heavy alcohol use is associated with disease progression [6]
 * Vaccination- Immunization for hepatitis A virus and hepatitis B virus should be given to patients without serologic evidence of immunity.
 * Modify risk factors for cardiovascular disease- Patients with NAFLD are at increased risk for cardiovascular disease and often have multiple risk factors for cardiovascular disease (eg, hypertension, hyperlipidemia). Regular management of patients diabetes includes optimization of blood glucose control.
 * Weight loss- Weight loss is the primary therapy for most patients with NAFLD. Weight loss is recommended for all patients with NAFLD who are overweight (body mass index [BMI] >25 kg/m2 ) or obese (BMI >30 kg/m2)[7-10]
 * Initial lifestyle interventions- It is advised to patients who are overweight or obese to lose five to seven percent of body weight at a rate of 0.5 to 1.0 kg per week (1 to 2 lb per week) through lifestyle modifications including dietary therapy and exercise

Global NASH market set to reach $18.3bn by 2026
The total size of the non-alcoholic steatohepatitis (NASH) market across the 7MM* is set to grow from $142.5M in 2016 to $17.8bn in 2026 at a compound annual growth rate (CAGR) of 60%, according to Thelansis Forecasting team.

The company’s latest report: ‘Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026’ states that a high level of unmet need for drugs in NASH, coupled with the expected launch of many new products across the 7MM, will drive huge levels of growth in the NASH market.